IRIS

Sfoglia per Titolo

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 9.308 a 9.327 di 25.478
Titolo Data di pubblicazione Autore(i) File
The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. 1-gen-2017 Straniero, L; Rimoldi, V; Samarani, M; Goldwurm, S; Di Fonzo, A; Krüger, R; Deleidi, M; Aureli, M; Solda, G; Duga, S; Asselta, R
Gefitinib ('Iressa', ZD1839) in elderly patients with progressive pretreated non-small-cell lung cancer: results from the Istituto Clinico Humanitas 1-gen-2003 Parra, Hs; Cavina, R; Zucali, P; Campagnoli, E; Latteri, F; Biancofiore, G; Abbadessa, G; Morenghi, E; Santoro, A
Gelatin-based plasma expander effectively reduces renal uptake of In-111-octreotide in mice and rats 1-gen-2006 van Eerd, Jem; Vegt, E; Wetzels, Jfm; Russel, Fgm; Masereeuw, R; Corstens, Fhm; Oyen, W; Boerman, Oc
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 1-gen-2004 Caffo, O; Santo, A; Binato, S; Zucchetti, M; Centonze, M; Lucenti, A; Giovannini, M; D'Incalci, M; Cartei, G; Cetto, G; Galligioni, E
Gemcitabine (GEM) and liposomal doxorubicin (PLO) in recurrent/metastatic breast carcinoma: A phase II study 1-gen-2005 Adamo, V; Ferrandina, G; Spada, M; Ferrau, F; Condemi, G; Di Lullo, L; Lorusso, D; Rossello, R; Garipoli, C; Scambia, G
Gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in recurrent metastatic breast carcinoma: A phase II study 1-gen-2005 Ferrandina, G.; Adamo, V.; Ferrau, F.; Condemi, G.; Di Lullo, L.; Rossello, R.; Lorusso, D; Garipoli, C.; Scambia, G.
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival 1-gen-2005 Ferrandina, G; Paris, I; Ludovisi, M; D'Agostino, G; Testa, A; Lorusso, D; Zanghi, M; Pisconti, S; Pezzella, G; Adamo, V; Breda, E; Scambia, G
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. 1-gen-2008 Zucali, Pa; Ceresoli, Gl; Garassino, I; De Vincenzo, F; Cavina, R; Campagnoli, E; Cappuzzo, F; Salamina, S; Soto Parra, Hj; Santoro, A
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma 1-gen-1999 Fossa, A; Santoro, A; Hiddemann, W; Truemper, L; Niederle, N; Buksmaui, S; Bonadonna, G; Seeber, S; Nowrousian, Mr
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives 1-gen-2005 Lorusso, D; Ferrandina, G; Fruscella, E; Marini, L; Adamo, V; Scambia, G
Gemcitabine in the treatment of refractory Hodgkins's disease: Results of a multicenter phase II study 1-gen-2000 Santoro, A; Bredenfeld, H; Devizzi, L; Tesch, H; Bonfante, V; Viviani, S; Fielder, F; Parra, Hs; Benoehr, C; Pacini, M; Bonadonna, G; Diehl, V
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial 1-gen-2005 Reni, M; Cordio, S; Milandri, C; Passoni, P; Bonetto, E; Oliani, C; Luppi, G; Nicoletti, R; Galli, L; Bordonaro, R; Passardi, A; Zerbi, A; Balzano, G; Aldrighetti, L; Staudacher, C; Villa, E; Di Carlo, V
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial 1-gen-2021 Pinto, C.; Zucali, P. A.; Pagano, M.; Grosso, F.; Pasello, G.; Garassino, M. C.; Tiseo, M.; Soto Parra, H.; Grossi, F.; Cappuzzo, F.; De Marinis, F.; Pedrazzoli, P.; Bonomi, M.; Gianoncelli, L.; Perrino, M.; Santoro, A.; Zanelli, F.; Bonelli, C.; Maconi, A.; Frega, S.; Gervasi, E.; Boni, L.; Ceresoli, G. L.
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 1-gen-2021 Vetrugno, G; Laurenti, P; Franceschi, F; Foti, F; D'Ambrosio, F; Cicconi, M; LA Milia, Di; Di Pumpo, M; Carini, E; Pascucci, D; Boccia, S; Pastorino, R; Damiani, G; De-Giorgio, F; Oliva, A; Nicolotti, N; Cambieri, A; Ghisellini, R; Murri, R; Sabatelli, G; Musolino, M; Gasbarrini, A; Gemelli-Against-Covid, Group; Armuzzi, A
Gender affects 13C-ketoisocaproic breath test for liver mitochondrial function 1-gen-2001 Candelli, M; Armuzzi, A; Nista, Ec; Zocco, Ma; Grieco, A; Miele, L; Pola, P; Gasbarrini, G; Gasbarrini, A
Gender affects C-13-ketoisocaproic acid breath test 1-gen-2007 Candelli, M; Armuzzi, A; Miele, L; Nista, Ec; Pignataro, G; Dal Verme, Lz; Grieco, A; Gasbarrini, G; Gasbarrini, A
Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies 1-gen-2011 Krzyszczak, Malgorzata E; Li, Yi; Ross, Steven J; Ceribelli, Angela; Chan, Edward K L; Bubb, Michael R; Sobel, Eric S; Reeves, Westley H; Satoh, Minoru
Gender balance in the editorial board of nuclear medicine journals 1-gen-2021 Evangelista, L.; Ekmekcioglu, O.; Kunikowska, J.
Gender difference for promoter methylation pattern of hMLH1 and p16 in sporadic MSI colorectal cancer 1-gen-2003 Laghi, L.; Bianchi, P.; Malesci, A.
Gender difference in drug use in hospitalized elderly patients 1-gen-2015 Santalucia, P.; Franchi, C.; Djade, C. D.; Tettamanti, M.; Pasina, L.; Corrao, S.; Salerno, F.; Marengoni, A.; Marcucci, M.; Nobili, A.; Mannucci, P. M.
Mostrati risultati da 9.308 a 9.327 di 25.478
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile